GHLF asked HSS to take definitive action to ensure that access to pharmacy services will remain when the current public health emergency formally ends.
Patient-Focused Economic and Policy Research
The Patient-Focused Economic and Policy Research Division
at the Global Healthy Living Foundation
At Global Healthy Living Foundation, we believe that equity, access, and affordability are paramount in the well-being of patients we serve. Unfortunately, economic and policy matters often undermine these principles to the detriment of patients. GHLF needs to examine how such issues impact patients’ financial and humanistic outcomes.
Our center promises to investigate such problems through primary research, which are then promoted through our various social media platforms as well as conventional media. Our researchers also address these important topics through opinion editorials, speaking engagements, and our world-class podcast series – Healthcare Matters. Our experts have published extensively and referenced the impact of biopharmaceuticals and health policies on costs and clinical outcomes in the most prominent medical sources and media publications, including the Clinical Economics and Outcomes Research, The Oncologist, Journal of Vaccines and Vaccinations, Health Economics Policy and Law, Health Science Journal, USA Today, Washington Examiner, Managed Healthcare Executive, The Hill and Morning Consult. They are sought-after speakers and have been invited to provide detailed presentations, briefings and expert reviews for the U.S. Congress, dozens of state legislatures, and at conferences and medical symposiums around the world.
Areas of Research Focus:
- Impact of accumulator adjustment program bans on insurance premiums
- How rebate contracting reform will lower healthcare costs and improve patient outcomes
- The economic impact of prior authorization policies in the U.S.
- COVID-19 vaccine patents
- How ensuring access to cancer diagnostics improves patient access and equity in healthcare
- Impact of Medicare benefit design on access
- How formulary exclusions undermine patient access
- How step therapy administrative focus destabilizes patient and healthcare professional decision-making
- Access to healthcare services in low-income communities across the United States
We continually develop new partnerships with academia, think tanks, and other like-minded organizations that believe in patient equity, access, and affordability as the cornerstone of a healthy society. If you would like to partner with us on a project, or have ideas for a topic we should research, contact Robert Popovian, Chief Science Policy Officer.
Peer-Reviewed Articles
- Pitts, Peter, Popovian, Robert and Winegarden, Wayne, Waiving COVID-19 Vaccine Patents: A Bad Idea and a Dangerous Precedent, Vol. 26 No. 2 (2021). Journal of Commercial Biotechnology
- Tharp, Lou and Rothblat, Zoe, Do patients benefit from legislation regulating step therapy? Health Economics, Policy and Law, April, 2021, pp 1-16, https://doi.org/10.1017/S1744133121000153
- Popovian, Robert and Winegarden, Wayne, An Estimate of the Net Benefits from Prior Authorization Policies in the U.S., Vol. 15 No. 4: 833. Health Science Journal, https://www.hsj.gr/medicine/an-estimate-of-the-net-benefits-from-prior-authorization-policies-in-the-us.pdf
- Winegarden, Wayne and Popovian, Robert, Reforming Rebate Contracting will Improve Drug Affordability, Vol. 14 No. 7: 783, Health Science Journal, https://www.hsj.gr/medicine/reforming-rebate-contracting-willimprove-drug-affordability.php?aid=34290
- Popovian, Robert, How to Ensure Equitable Access to Vaccines, Volume 11(6), December 2020, Journal of Vaccines and Vaccination. https://www.longdom.org/open-access/how-to-ensure-equitable-access-to-covid19-vaccine-59774.html
- Popovian, Robert and Hering, Dave, Enhance and Expand Access to Vaccines, Volume S5, November 2020, Journal of Vaccines and Vaccination. https://www.longdom.org/open-access/enhance-and-expand-access-to-vaccines.pdf
- Winegarden, Wayne and Popovian, Robert, Reforming Rebates will Improve Drug Affordability. September 2020, Pacific Research Institute Paper. https://medecon.org/wp-content/uploads/2020/09/DrugRebates_F.pdf
- McCombs Jeff, Dang Richard, Popovian, Robert, Is the U.S. Ready to Quickly Vaccinate its Population Against COVID-19? May 2020, Schaeffer Institute Paper. https://healthpolicy.usc.edu/research/is-the-u-s-ready-to-quickly-vaccinate-its-population-against-covid-19/
- McCombs Jeff, Myerson Rebecca, Xu Yifan, Popovian Robert, Value Based Contracting in Healthcare What is it and how can it be Achieved. June 2019, Schaeffer Institute Paper. https://healthpolicy.usc.edu/research/value-based-contracting-in-healthcare-what-is-it-and-how-can-it-be-achieved/
- McKinley Laura, Kelton John and Popovian Robert. Sowing confusion in the field: the interchangeable use of biosimilar terminology. January 2019. Current Medical Research and Opinion. https://pubmed.ncbi.nlm.nih.gov/30556742/
- Cazap Eduardo, Jacobs Ira, McBride Ali, Popovian, Robert and Sikora Karol. Global Acceptance of Biosimilars: Importance of Regulatory Consistency, Education, and Trust. May 2018. The Oncologist, http://theoncologist.alphamedpress.org/content/early/2018/05/16/theoncologist.2017-0671
- Dranitsaris G, Jacobs I, Kirchhoff C, Popovian R, Shane LG. Drug tendering: drug supply and shortage implications for the uptake of biosimilars. September 29, 2017. Clinical Economics and Outcomes Research, https://www.ncbi.nlm.nih.gov/pubmed/29033595
- Simoens S, Jacobs I, Popovian R, Isakov L, Shane LG. Assessing the Value of Biosimilars: A Review of the Role of Budget Impact Analysis. June 28, 2017. PharmacoEconomics, https://www.ncbi.nlm.nih.gov/pubmed/28660473
- Boccia R, Jacobs I, Popovian R, G de Lima Lopes. Can Biosimilars Help Achieve the Goals of the U.S. Healthcare Reform? Cancer Management and Research. June 1, 2017, 9:197-205, https://www.oncologynurseadvisor.com/home/cancer-types/general-oncology/can-biosimilars-help-achieve-the-goals-of-us-health-care-reform/ .
- James G. Stevenson,PharmD, Robert Popovian, PharmD, Ira Jacobs, MD, Susan Hurst, RPh, PhD, Lesley G. Shane, Biosimilars, Practical Considerations for Pharmacists. Annals of Pharmacotherapy, February 2017, http://journals.sagepub.com/doi/full/10.1177/1060028017690743.
- Cohen Hillel, Beydoun Donna, Chien David, Lessor Tracy, McCabe Dorothy, Muenzberg Michael, Popovian Robert and Uy Jonathan. Awareness, Knowledge, and Perceptions of Biosimilars Among Specialty Physician. Advances In Therapy. January 2017, Volume 33, Issue 12, pp 2160–2172
- Abstract: Nichol MB, Shi S, Knight TK, Popovian R, and Morita R. Impact of Market Forces on Statin persistence patterns in a California Medicaid population. Value In Health. 2004, Vol 7, No 3, page 334.
- Setter SM, Corbett C, Gates, B, Terriff C, Johns CA, Sclar DA, and Popovian R. Nonsteriodal Anti-inflammatory Drugs: The Need for Assessment and Education. Home Care Provider. 2001, VOL 6; PART 3, pages 100-105.
- Setter SM, Corbett CF, Terriff CM, Gates BJ, Johns C, Broemeling L, Maccini D and Popovian R. Abstract – Knowledge of nonsteroidal anti-inflammatory drugs in at risk elders: effectiveness of individualized patient education. Pharmacotherapy. Volume 20 (10), 2000, page 1229.
- Abstract: Gerding, G, Carlson, J, Carter, C, Doak, M, Frederick, K and Popovian, R. Abstract – Treatment of Osteoarthritis and Rheumatoid Arthritis in a Long-term Care Setting. The Consultant Pharmacist. Volume 15 (9), 2000, page 933.
- Johnson, KA, Nichol MB, Popovian R and Liu G. Letter to the Editor: The Impact of Pharmaceutical Capitation to Primary Medical Groups on the Health Care Expenditures of Medicare HMO Enrollees. Journal of Managed Care Pharmacy. Volume 6 (1), January/February 2000, pages 8-9.
- Popovian R, Johnson, KA, Nichol MB and Liu G. The Impact of Pharmaceutical Capitation of Primary Medical Groups on the Health Care Expenditures of Medicare HMO Enrollees. Journal of Managed Care Pharmacy. Volume 5 (5), September/October 1999, pages 414-419.
- Niedermann MS, McCombs JS, Unger AN, Kumar A and Popovian R. Treatment cost of acute exacerbations of chronic bronchitis. Clinical Therapeutics. Volume 21 (3), March 1999 1998, pages 576-591.
- Niedermann MS, McCombs JS, Unger AN, Kumar A and Popovian R. The Cost of Treating Community Acquired Pneumonia. Clinical Therapeutics. Volume 20 (4), July/August 1998, pages 820-837.
- Abstract: Popovian R, Hay, JW, Sung JCY and Jaresko GS,. Cost-effectiveness analyses of penicillin prophylaxis in dental procedures for prevention of infective endocarditis in mitral valve prolapse patients. Pharmacotherapy. Volume 17 (1), 1997, page 192.
- Abstract: Jaresko GS, Sung JC, Tajbakhsh-Werner G, Popovian R and Goldshtein G. Implementing an Interdisciplinary, pharmacy directed Enterobactor surveillance program. International Pharmaceutical Abstracts. Volume 33 (21), 1996, page 2245.
- Abstract: Jaresko GS, Popovian R, Nichol MB and Riley S. Factors influencing outcomes in patients with type I -lactamase producing gram negative bacteremia. Pharmacotherapy. Volume 15 (1), 1995, page 113.
- Popovian R, Bedikian A, Gill MA. Management of Diabetic Foot Ulcers. California Pharmacist. February 1993, pages 28-35.
Opinion Editorials
- We Need to Avert the Next Public Health Disaster, Feb 2022, Insidesources, https://insidesources.com/we-need-to-avert-the-next-public-health-disaster/
- Benefit Design In Medicare Exacerbates Vaccine Access Inequity, Oct 2021, Ousourcedpharma, https://www.outsourcedpharma.com/doc/benefit-design-in-medicare-exacerbates-vaccine-access-inequity-0001
- Vaccines are the future of health care, September 2021. The Hill, https://thehill.com/opinion/healthcare/572701-vaccines-are-the-future-of-health-care?rl=1
- Why Should We Rescue The Legislative Intent Of The BPCIA? Bioprocess, July 2021 https://www.bioprocessonline.com/doc/why-should-we-rescue-the-legislative-intent-of-the-bpcia-0001
- Waiving Covid-19 Vaccine Patents Is a Bad Idea and Sets a Dangerous Precedent, Town Hall, June 2021. https://townhall.com/columnists/peterpitts/2021/06/19/waiving-covid19-vaccine-patents-is-a-bad-idea-and-sets-a-dangerous-precedent-n2591208
- The US Drug Pricing System Needs to Be Fixed. Outsourced Pharma, June 2021. https://www.outsourcedpharma.com/doc/the-u-s-drug-pricing-system-needs-to-be-fixed-0001
- Blurring the Lines between Medical Practice and Insurance Coverage. Healthcare Business Today, April 2021. https://www.healthcarebusinesstoday.com/blurring-the-lines-between-medical-practice-and-insurance-coverage/
- We Need Greater Transparency to Improve the US Healthcare System, Insidesources, March 2021 https://insidesources.com/we-need-greater-transparency-to-improve-the-u-s-healthcare-system/
- No, Biologics are Not Natural Monopolies. Bioprocess, April 2021. https://www.bioprocessonline.com/doc/no-biologics-are-not-natural-monopolies-0001
- The pandemic will end at your local pharmacy — if we let it. March 2021, Washington Examiner, https://www.washingtonexaminer.com/opinion/op-eds/the-pandemic-will-end-at-your-local-pharmacy-if-we-let-it
- Separating Fact From Fiction on Drug Costs, Texas Tribune, Trib Talk, Nov, 2017, https://www.tribtalk.org/2017/11/01/separating-fact-from-fiction-on-drug-costs/
Morning Consult – Opinion Editorials
-
- When Making Policy Decisions, Quality and Context of Data Should Be Scrutinized, November 2021
- We Should Not Lose Sight of the Upcoming Flu Season, September 2021
- It is Time for Outcomes-Based Reimbursement for Biopharmaceuticals, July 2021
- Innovation in Cancer Diagnostics Is the First Step in Ensuring Equity for All Patients, June 2021
- Stop Failing Patients, May 2021
- We Can Address Vaccine Equity, April 2021
- President Biden’s Bipartisan Opportunity to Reduce Patients’ Drug Costs, March 2021
- Five Policy Priorities to Ensure Equitable Access to a Covid-19 Vaccine, November 2020
- 12 Principles for Better Employer Stewardship of Health Care Benefit, October 2020
- Growing Body of Data on the Important Drug Cost Questions, July 2020
- Routine Vaccinations Shouldn’t be Another Victim of Covid-19, June 2020
- New Data Supports Adopting “Share The Savings” Reform, May 2020
- To Boost Adult Vaccination, Empower Pharmacists, March 2020
- Sustainable Solutions to Drug Shortages, February 2020
- What Are Authorized Generics and Why Should You Care? January 2020
- Debunking the Myth of Who Funds Biomedical Innovation, December 2019
- Let The Facts Get in Way of a Get in The Way of Healthcare Spending Story, October 2019
- We Still Need Rebate Reform, August 2019
- A Modern Payment Model for 21st Century Cures, June 2019
- Follow the Evidence on Premium Impact, May 2019
- Economic Analysis Fall Short When it Comes to Medicines’ Value, February 2019
- A Private-Sector Solution to Address Drug Spending That Everyone Is Ignoring, January 2019
- R&D Costs: Not a Simple Calculation, November 2018
- Anti-Clawback Laws — A Step in the Right Direction, September 2018
- Good Ideas Gone Bad in Health Care, June 2018
- Comparing U.S. Healthcare Costs to Amounts in Other Countries Falls Short, May 2018
- We Can Address Vaccination Disparities through Policy Changes, Education, April 2018
- Time to Pass PBM Savings Back on to Patients, March 2018
- Reality, Not Rhetoric, of Drug Cost Trends, Feb 2018
- Gene Therapy is a Game Changer, Nov 2017
- Medical Treatments Must be Made by Providers and Patients, Oct 2017
- The Future of Manufacturing a Medicine in America, July 2017
- Reauthorizing PDUFA is Key to a Healthier U.S. – May 2017
- Real Facts Needed in Drug Price Policy Debate – April 2017
- Let the ‘Buyer Beware’ for Health Care Purchases – March 2017
- How to Achieve Value Based Reimbursement – Feb 2017
- A Little Prevention Goes a Long Way to Reduce Costs – Dec 2016
- The Facts Are Getting in the Way of a Good Story – Oct 2016
- Five Important Questions on Health Care Costs – Sept 2016
- In Drug Development, It’s About Time – July 2016
- No Substitute for Better Study to Protect Patients – June 2016
- Beyond Patent Life, Biosimilars Policy Requires a Nuanced Touch – May 2016
- The System is Working – A Not-So-Surprising Finding – April 2016
- Dedicated Scientists Driven to Discover Cures – March 2016
- The Economics of Innovation – Feb 2016
- The Rest of the Research and Development Investment Story – Dec 2015
- We Have Smart Phone and Soon Will Have Smart Cars, So Why Not Smart Evidence! – Oct 2015
- Transparency for All Healthcare Costs and Outcomes – Sept 2015
- A Distinction That Makes a Difference in Healthcare – July 2015
- Sound Policy and Not Rhetoric Will Fix the Healthcare Cost Woes – June 2015
- Proper Incentives for Proper Pain Treatment – May 2015
- Self-Care Leads to Better Health – April 2015
- Discrimination in Healthcare Insurance Coverage Needs to End – March 2015
- It’s a Small World After All – Feb 2015
- Cures Without Access No Cure At All – Jan 2015
- A Spoonful of Medication Adherence Policy – Nov 2014
- Stepping Towards Failure – Oct 2014
- Partnership Needed to Access Real World Data – Sept 2014
- Paying for Value Not Volume – July 2014
- Enabling US Biopharmaceutical Innovation – June 2014
Interviews
- Interview: Life Science Leader, November 27, 2019, Biosimilar Competition Is Here To Stay In 2020. https://www.lifescienceleader.com/doc/biosimilar-competition-is-here-to-stay-in-0001
- Interview: Managed Healthcare Executive, Jan 28, 2018, Pfizer VP Robert Popovian Talks Value-Based Reimbursement https://www.managedhealthcareexecutive.com/biosimilars/pfizer-vp-robert-popovian-talks-value-based-reimbursement
Blogs
- Aiming Drug Price Reform at the Right Target, September 2021. https://www.progressivepolicy.org/blogs/aiming-drug-price-reform-at-the-right-target/
- Reducing Costs, Enhancing Care through Utilization of Biosimilars, North Carolina Chamber of Commerce, September 2020. https://ncchamber.com/2020/09/24/reducing-costs-enhancing-care-through-utilization-of-biosimilars/
- Enhance and Expand Access to Vaccine, Healthcare Leadership Council, September 2020. https://www.hlc.org/post/enhance-and-expand-access-to-vaccines/
- Prior Authorization Changes Driven by the COVID-19 Pandemic, July 2020, Policy and Medicine, https://www.policymed.com/2020/07/prior-authorization-changes-driven-by-the-covid-19-pandemic.html
- Why Beating Covid-19 Will Require Strong Public Private Partnership. May 2020, Daily Signal. https://www.dailysignal.com/2020/05/27/why-beating-covid-19-will-require-strong-public-private-partnership/
- Underutilization of Prevention, Healthcare Leadership Council, March 2020. https://www.hlc.org/post/guest-post-the-underutilization-of-prevention/
Healthcare Matters – GHLF Podcast
Podcasts
- Podcast Series – Global Healthy Living Foundation – Healthcare Matters
- S1, E1: Trusting the Vaccines, Apple Podcasts http://ow.ly/5J8p30rWkqp or Spotify http://ow.ly/1x6l30rWkqF
- S1, E2: Bipartisan Healthcare: Policy or Pipedream? Apple Podcasts https://cutt.ly/1TxNabH or Spotify https://cutt.ly/CTxMebZ
- S1, E3: The Flaws in Fail First Policies, Apple Podcasts https://cutt.ly/pTxJTIQ or Spotify https://cutt.ly/rTx7o2K
- S1, E4: Out of Pocket Barrier to Vaccines, Apple Podcasts https://cutt.ly/jTxJFy7 or Spotify https://cutt.ly/6Tx7f84
- S1, E5: Mind Boggling: Patients In The Dark, Apple Podcasts https://cutt.ly/RTxJtxk or Spotify https://cutt.ly/nTx7zna
- S1, E6: The Gimmick of Paying Patients, Apple Podcasts https://cutt.ly/vT6utsx or Spotify https://cutt.ly/rT6uj64
- S1, E7: The “1-2 Punch” To Help Patients, Apple Podcasts https://cutt.ly/vYFDLAs or Spotify https://cutt.ly/8YFDBUq
- S1, E8: The Risks of Switching Patients Who Are Stable on Their Medication, Apple Podcasts https://cutt.ly/1UEA9uw or Spotify https://cutt.ly/gUEStZj
- S1, E9: Build Back Better: Will Congressional Action Help Patients? Apple Podcasts https://cutt.ly/yUESaew or Spotify https://cutt.ly/aUESkMc
- S1, E10: Three Big Misses of Build Back Better For Patients, Apple Podcasts https://cutt.ly/fULINui or Spotify https://cutt.ly/0ULI8Vz
- S2, E1: In Drug Development, It’s About Time, Apple Podcasts https://cutt.ly/bIo6VN3 or Spotify https://cutt.ly/LIo62LU
- S2, E2: A Deep Dive Into COVID-19 Vaccines, Apple Podcasts https://cutt.ly/1I6RaDq or Spotify https://cutt.ly/qI6Ic9w
- S2, E3: Status of COVID Treatments, Apple Podcasts https://cutt.ly/RO1q9Ey or Spotify https://cutt.ly/sO1tmqE
- S2, E4: Patients Stuck with Health Care Deductible Bills, Apple Podcasts https://cutt.ly/ePDvFbm or Spotify https://cutt.ly/2PDvCWV
- S2, E5, UnQALYfied: Putting a Price on Patients Life, Apple Podcasts https://cutt.ly/BD6yvs1 or Spotify https://cutt.ly/ND6yYCJ
- S2, E6, Non-Medical Switching: What It Is and How It Harms Patients, Apple Podcasts https://cutt.ly/KD6yAD8 or Spotify https://cutt.ly/tD6yHj4
- S2, E7, “It’s Criminal”- Non-Medical Switching and Mental Health, Apple Podcasts https://cutt.ly/vFEwRM3 or Spotify https://cutt.ly/9FEwJBC
- Podcast, Evolving After the Pandemic, The Business of Pharmacy, https://lnkd.in/egnPCKRZ
- Podcast, House Calls: Be Your Own Advocate, https://cutt.ly/zGyUCia or https://cutt.ly/BGyU9sN
- Podcast, Breaking Down Biosimilars, Episode 5, https://open.spotify.com/episode/6Z7fUFux16doPTWwdiKgW4
- Podcast, The False Promise of the Current Drug Pricing Reforms, Patients Rising Now, https://www.patientsrisingpodcast.org/the-false-promise-of-current-drug-pricing-reforms/?mc_cid=ab675c7604&mc_eid=d375b4043c
- Podcast, Debunking the Myth of Who Funds Biomedical Innovation, Ideagen, https://www.youtube.com/watch?v=FdhNBoxgc8U
- Podcast, Drug Pricing Reforms, Good and Bad Ideas with Dr. Robert Popovian, The American Consumer Institute, https://open.spotify.com/episode/02dbUcKWwQBn06OacxxmRv
- Podcast, The Business of Pharmacy, Manufacturer Drug Pricing https://anchor.fm/bizofpharmpod/episodes/Manufacturer-drug-pricing–Robert-Popovian–PharmD–Vice-President-US-Government-Relations–Pfizer-enmfbv
- Podcast, President Trump’s executive orders and the impact on drug costs for patients, Patients Rising Now https://patients-rising-podcast.simplecast.com/episodes/the-vaccine-finish- line?utm_source=Twitter&utm_medium=Podcast_Ep30&utm_campaign=Popovian September 2020
- Podcast, What Goes Into Drug Prices, Patients Rising Now https://podcasts.apple.com/us/podcast/what-goes-into-drug-prices/id1500936486?i=1000490949331 September 2020
- Podcast, Value Frameworks, Massachusetts Prostate Cancer Coalition https://masspcc.org/news/464923/August-2019-Podcast—Health-Value-Assessments.htm
- Presenter, National Association Boards of Pharmacy, A Closer Look at FDA’s Interchangeable Biosimilar Approvals, February 2022
- Presenter/Moderator, World Vaccines Congress, December 2021
- Keynote speaker, Northeast Business Group on Health, Pharmacy Benefits Strategie Now and Later, December 2021
- Presentation, 2021 IEEE Healthcare: Blockchain & AI – Decentralized Clinical Trials: Opportunities and Challenges https://ieeetv.ieee.org/channels/ieee-future-directions/2021-ieee-healthcare-blockchain-ai-decentralized-clinical-trials-opportunities-and-challenges
- Festival of Biologics Conference 2021. https://twitter.com/PopovianPharmD/status/1376880723269980163
- Wisconsin, July 21, 2020, Meeting of Governor’s Task Force on Reducing Prescription Drug Prices https://www.youtube.com/watch?v=4gYd8FX4QEg&feature=youtu.be
- NORD (National Organization of Rare Diseases) Summit, The Time is Now: Addressing Affordability While Sustaining Innovation
- Concordia University The 2019 Healthcare Economics Summit – Drug Pricing Panel http://rxthinktank.org/the-2019-healthcare-economics-summit-in-review/
- National Minority Quality Forum Annual Meeting (2019) – Leadership Summit & Health Braintrust: Spring Health Braintrust Panel 1 https://www.youtube.com/watch?v=QY5kyqCMk14
- The Hill, Overcoming Obstacles: Patient Access to Innovation, March 2019 https://www.youtube.com/watch?list=PL38N7FY-na0MjmyrYCxgShAaYezHHE6Ci&v=L6oG-PwX2D0&feature=emb_logo
- Financial Times, Financial Pressures and Healthcare Reform, September 2018
- FDA/CMS Summit, Obstacles, Reimbursement, and Leverage Opportunities for Boosting Competition and Adoption of Biosimilars in US Market, December 2017
- Sino-American Biotechnology and Pharmaceutical Professional Association, Market Based Solutions in Making Medicines Affordable, Lowering Healthcare Costs and Protecting Biopharmaceutical Innovation, June 2017
- Texas Healthcare and Biosciences Summit: Value of Innovation and Drug Development, 2016, 2017, 2018, 2019 and 2021
- Center for Economic Development CED 2016 Fall Policy Conference: Quality, Affordable Care for America’s Seniors https://www.youtube.com/watch?v=BlesgAfLWgE
- Deloitte Center for Health Solutions and The Network for Excellence in Health Innovation: Delivering medical innovation In a Value-Based World, February 15, 2016
- Building a 21st Century Health Care System: Aligning Policy, Accelerating Cures, Delivering Hope, August 2014, Using Data to Support Patient-Centered Innovation – Manhattan Institute and Tufts School of Medicine
- Connected Health, Better Adherence – NEHI, Prescription for Better Health and PhRMA, Jan 2014, The Future: How should we shape health IT policy to support proper medication use and improved adherence?
- American Association of Colleges of Pharmacy, 2011 Annual Meeting, US Policies Surrounding Pharmaceutical Innovation
- Academic & Industry Intersection Conference: Profiles of Success, Georgia BIO and Emory University, 2011, Future of Industry and Physician Relations “Our Path Forward”
- Minnesota Physician Publishing, 2009, Health care reform panel discussion
- American Psychiatric Association, Annual Meeting, 2005, Promises and Politics of Evidence-Based Medicine
| Venue | Date | Title | Web page |
| Los Angeles Times | 9/10/1995 | Drug Use Weakened Allegations of Abuse | http://articles.latimes.com/1995-09-10/local/me-44355_1_eileen-zelig
|
| USA Today | 12/9/2004 | Web site compares drugs for ‘best buys’ | http://www.usatoday.com/money/industries/health/drugs/2004-12-09-drugs-usat_x.htm
|
| The Grand Rapids Press | 3/9/2008 | Health plans push harder for use of generic drugs, not as ‘equivalents’ but as ‘alternatives’ | http://blog.mlive.com/grpress/2008/03/health_plans_push_harder_for_u.html
|
| Pink Sheet | 2/21/2011 | Lobbying Around State eRx Legislation Pits Payers Against Manufacturers | |
| Bloomberg News | 3/4/2011 | Pfizer-Backed Bills Threaten Medicaid Generic Savings: Insight | http://www.allscripts.com/content/dam/allscripts/documents/Pfizer-BackedBillsThreatenMedicaidGenericSavings.pdf
|
| First Word – Dossier | 1/1/2012 | Academic Detailing: Pharma Fights Back | http://www.firstwordplus.com/academic_detailing_pharma_fights_back.do |
| Pink Sheet | 8/27/2014 | Biomedical Reform Legislation May Be Piecemeal But Holistic | http://energycommerce.house.gov/blog/path2cures-what-they%E2%80%99re-saying-beantown
http://www.focr.org/news/pink-sheet-biomedical-reform-legislation-may-be-piecemeal-holistic
|
| Public Affairs Council | 11/13/2017 | Do Big Donors Compromise Think Tanks? | https://pac.org/impact/do-big-donors-compromise-think-tanks |
| Managed Healthcare Executive | 1/28/2018 | Pfizer VP Robert Popovian Talks Value-Based Reimbursement | http://managedhealthcareexecutive.modernmedicine.com/managed-healthcare-executive/news/pfizer-vp-robert-popovian-talks-value-based-reimbursement |
| Politico | 5/9/2018 | A Better Prescription: Biosimilars and a Pathway to Patient Choice | http://www.politico.com/sponsor-content/2018/05/a-better-prescription |
| The Hill | 3/6/2019 | Gottlieb: Drug rebates not benefiting sicker patients | https://thehill.com/policy/healthcare/432857-gottlieb-drug-rebates-not-benefiting-sicker-patients#.XIAaK4Feav0.twitter |
| Biosimilars Review and Report | 4/6/2021 | Biosimilars, Employers, Medicaid, and Rebates | https://biosimilarsrr.com/2021/04/06/biosimilars-employers-medicaid-and-rebates/
|
| Pharmacy Today | 5/12/2021 | Cash-based pharmacies deliver transparency, savings
|
https://www.pharmacytoday.org/article/S1042-0991(21)00299-1/fulltext |
| Ohio Capital Journal | 7/22/2021 | Chucking insurance | https://ohiocapitaljournal.com/2021/06/22/chucking-insurance/
|
| Pharmacy Today | 10/01/2021 | Walmart–Novo Nordisk insulin offers deep discounts to select few | https://www.pharmacytoday.org/article/S1042-0991(21)00729-5/fulltext |
| accessWDUN.com | 12/31/2021 | Covid-19 vaccines and antiviral treatments | https://accesswdun.com/article/2021/12/1066458/listen-clinical-pharmacist-discusses-between-approved-covid-19-vaccines-and-novovax
|
| The Center for Biosimilars | 1/12/2022 | Biosimilar Progress and Education in the United States | https://cutt.ly/XIpqoxL |
| Pharmacy Today | 3/1/2022 | Most physicians unable to estimate patients’ out-of-pocket costs: How pharmacists can help | https://www.pharmacytoday.org/article/S1042-0991(22)00277-8/fulltext |
SUBSCRIBE TO GHLF
Was this article helpful?
YesNo
Related Posts
